Genelux Corporation (GNLX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genelux Corporation (GNLX) trades at $3.02 with AI Score 15/100 (Grade F). Genelux Corporation is a clinical-stage biopharmaceutical company specializing in oncolytic viral immunotherapies. Market cap: $113.41M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for GNLX: GNLX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNLX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GNLX: 1/1 perspectives are bearish.
How is this calculated? →Genelux Corporation (GNLX) Healthcare & Pipeline Overview
Genelux Corporation is a clinical-stage biopharmaceutical firm focused on developing innovative oncolytic viral immunotherapies, with its lead candidate, Olvi-Vec, targeting difficult-to-treat solid tumors. The company operates in the competitive biotechnology sector, striving to advance novel cancer treatments.
What Is the Investment Thesis for GNLX?
Genelux Corporation presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of Olvi-Vec, their lead product candidate, for ovarian cancer and non-small-cell lung cancer. Positive clinical trial results and regulatory approvals would significantly increase the company's valuation. The company's small market capitalization of $113.41M reflects the inherent uncertainty associated with drug development. Key catalysts include the progression of Olvi-Vec through clinical trials and potential partnerships with larger pharmaceutical companies. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional capital to fund ongoing research and development. The extremely negative profit and gross margins highlight the pre-revenue nature of the company.
Based on FMP financials and quantitative analysis
GNLX Key Highlights
- Market capitalization of $113.41M, reflecting its status as a small-cap biotechnology company.
- Focus on oncolytic viral immunotherapies, a promising area in cancer treatment.
- Lead product candidate, Olvi-Vec, targeting ovarian cancer and non-small-cell lung cancer.
- Profit Margin of -397225.0%, indicative of a clinical-stage company with significant R&D expenses.
- Gross Margin of -3550.0%, reflecting the lack of product sales and high cost of research and development.
Who Are GNLX's Competitors?
GNLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| BMY Bristol-Myers Squibb Company | $56.70 | -2.46% | 116B | 88 |
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNLX's Key Strengths?
- Proprietary oncolytic virus technology platform.
- Lead product candidate (Olvi-Vec) targeting significant unmet medical needs.
- Experienced management team with expertise in drug development.
- Focus on a promising area of cancer therapy (immunotherapy).
What Are GNLX's Weaknesses?
- Clinical-stage company with no currently approved products.
- High reliance on the success of Olvi-Vec.
- Limited financial resources.
- Small number of employees.
What Could Drive GNLX Stock Higher?
- Clinical trial results for Olvi-Vec in ovarian cancer.
- Clinical trial results for Olvi-Vec in non-small-cell lung cancer.
- Advancement of V2ACT Immunotherapy into clinical trials.
- Continued research and development of oncolytic viral immunotherapies.
- Potential partnerships with larger pharmaceutical companies.
What Are the Key Risks for GNLX?
- Financial-distress signal — its Altman Z-Score of -8.10 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Olvi-Vec or other product candidates.
- Regulatory hurdles and delays in obtaining marketing approvals.
- Competition from other biotechnology and pharmaceutical companies.
- Need for additional capital to fund research and development.
- Patent expiration risks for key technologies.
What Are the Growth Opportunities for GNLX?
- Expansion of Olvi-Vec into additional indications: Beyond ovarian cancer and non-small-cell lung cancer, Olvi-Vec could be explored for efficacy in other solid tumor types. The global market for solid tumor therapies is estimated to reach $400 billion by 2028, providing a significant opportunity for Genelux to expand its market reach and revenue potential. This expansion would require further clinical trials and regulatory approvals, but could significantly increase the value of Olvi-Vec.
- Advancement of V2ACT Immunotherapy for pancreatic cancer: Pancreatic cancer is a particularly challenging disease with limited treatment options. Successful development of V2ACT Immunotherapy could address a critical unmet need and capture a significant share of the pancreatic cancer therapeutics market, projected to reach $4 billion by 2027. This growth opportunity depends on positive clinical trial outcomes and the ability to demonstrate superior efficacy compared to existing treatments.
- Strategic partnerships with larger pharmaceutical companies: Genelux could benefit from partnering with larger pharmaceutical companies for late-stage clinical development, manufacturing, and commercialization of its products. Such partnerships could provide access to significant financial resources, expertise, and established distribution networks. The timeline for securing such partnerships is uncertain, but could accelerate the development and commercialization of Genelux's pipeline.
- Development of V-VET1 for hematologic and solid cancers: Expanding the application of V-VET1 to treat both hematologic and solid cancers presents a broad growth opportunity. The market for hematologic cancer therapies is projected to reach $80 billion by 2029. Success in this area would require demonstrating the safety and efficacy of V-VET1 in relevant clinical trials, and could position Genelux as a leader in oncolytic virus-based cancer therapies.
- Exploration of combination therapies: Combining oncolytic viral immunotherapies with other cancer treatments, such as checkpoint inhibitors or chemotherapy, could enhance their efficacy and broaden their applicability. This approach could lead to synergistic effects and improved patient outcomes. The market for combination cancer therapies is rapidly growing, driven by the increasing understanding of cancer biology and the development of novel therapeutic agents. Genelux could explore such combinations to maximize the potential of its pipeline.
What Opportunities Does GNLX Have?
- Expansion of Olvi-Vec into additional indications.
- Advancement of V2ACT Immunotherapy and V-VET1.
- Strategic partnerships with larger pharmaceutical companies.
- Growing market for cancer immunotherapies.
What Threats Does GNLX Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology and pharmaceutical companies.
- Need for additional capital.
What Are GNLX's Competitive Advantages?
- Proprietary oncolytic virus technology platform.
- Patent protection for Olvi-Vec and other product candidates.
- Clinical data demonstrating the safety and efficacy of their therapies.
- Expertise in oncolytic viral immunotherapy development.
What Does GNLX Do?
Genelux Corporation, established in 2001 and headquartered in Westlake Village, California, is a clinical-stage biopharmaceutical company dedicated to pioneering next-generation oncolytic viral immunotherapies. The company's primary focus is on developing treatments for patients battling aggressive and difficult-to-treat solid tumor types. Their lead product candidate, Olvi-Vec, represents a significant advancement in cancer therapy, utilizing a proprietary, modified strain of the vaccinia virus. Olvi-Vec is currently being developed for the treatment of ovarian cancer and non-small-cell lung cancer, two indications with substantial unmet medical needs. In addition to Olvi-Vec, Genelux is actively developing V2ACT Immunotherapy, a novel therapeutic approach targeting pancreatic cancer. The company is also advancing V-VET1, another oncolytic virus-based therapy, for the treatment of hematologic and solid cancers. Genelux's strategic focus on oncolytic viral immunotherapies positions it within a rapidly evolving field of cancer treatment, leveraging the body's own immune system to combat tumors. The company's pipeline reflects a commitment to addressing significant challenges in cancer care through innovative and targeted therapies.
What Products and Services Does GNLX Offer?
- Develop next-generation oncolytic viral immunotherapies.
- Focus on treating aggressive and difficult-to-treat solid tumor types.
- Develop Olvi-Vec, a modified vaccinia virus, for ovarian cancer and non-small-cell lung cancer.
- Develop V2ACT Immunotherapy for pancreatic cancer.
- Develop V-VET1 to treat hematologic and solid cancer.
- Conduct clinical trials to evaluate the safety and efficacy of their therapies.
How Does GNLX Make Money?
- Develop proprietary oncolytic viral immunotherapy products.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through milestone payments and royalties on product sales (if approved).
What Industry Does GNLX Operate In?
Genelux Corporation operates within the dynamic and competitive biotechnology industry, specifically focusing on oncolytic viral immunotherapies. This sector is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Genelux competes with other biotechnology and pharmaceutical companies developing novel cancer treatments, including those utilizing viral vectors and immunotherapy approaches. The success of Genelux depends on its ability to differentiate its products, demonstrate clinical efficacy, and secure regulatory approvals in a timely manner.
Who Are GNLX's Key Customers?
- Patients suffering from aggressive and/or difficult-to-treat solid tumor types.
- Hospitals and oncology clinics.
- Pharmaceutical companies (potential partners or licensees).
F-Score 3/9Financial Health
Genelux Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.10 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -98.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -24.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -32.5%, the inverse of the P/E and a quick read on earnings relative to price.
Genelux Corporation (GNLX) Valuation Context
Valued at $113.41M, GNLX is classified as a micro-cap stock. Relative to its peer group, GNLX's quantitative score of 15/100 is below the peer average of 73/100.
FY2026 estForward Outlook
Wall Street analysts project Genelux Corporation revenue of about $2.6M for fiscal 2026, with EPS near $-0.81. The estimate reflects 5 contributing analysts.
GNLX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary oncolytic virus technology platform.
- Lead product candidate (Olvi-Vec) targeting significant unmet medical needs.
- Experienced management team with expertise in drug development.
- Focus on a promising area of cancer therapy (immunotherapy).
Bear Case
- Clinical-stage company with no currently approved products.
- High reliance on the success of Olvi-Vec.
- Limited financial resources.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
GNLX Latest News
No recent news available for GNLX.
GNLX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNLX.
Price Targets
Wall Street price target analysis for GNLX.
GNLX MoonshotScore
What does this score mean?
The MoonshotScore rates GNLX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thomas D. Zindrick
CEO
Thomas D. Zindrick serves as the CEO of Genelux Corporation, bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in several biotechnology companies, with a focus on oncology drug development and commercialization. He has a proven track record of successfully navigating the complexities of clinical trials, regulatory approvals, and market access. Mr. Zindrick holds advanced degrees in business and science, providing him with a comprehensive understanding of the biotechnology landscape.
Track Record: Under Mr. Zindrick's leadership, Genelux has advanced its lead product candidate, Olvi-Vec, through clinical trials and expanded its pipeline with the development of V2ACT Immunotherapy and V-VET1. He has also focused on securing strategic partnerships and raising capital to support the company's research and development efforts. His tenure has been marked by a commitment to innovation and a focus on addressing unmet medical needs in cancer care.
Genelux Corporation Healthcare Stock: Key Questions Answered
What does Genelux Corporation do?
Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing innovative oncolytic viral immunotherapies for the treatment of various cancers. Their lead product candidate, Olvi-Vec, is a modified strain of the vaccinia virus designed to selectively infect and destroy cancer cells while stimulating an immune response. The company's pipeline also includes V2ACT Immunotherapy for pancreatic cancer and V-VET1 for hematologic and solid cancers. Genelux aims to provide new treatment options for patients with aggressive and difficult-to-treat tumors.
What do analysts say about GNLX stock?
As a clinical-stage biopharmaceutical company, Genelux's valuation is primarily driven by the potential success of its drug pipeline. Analysts' perspectives will likely focus on the clinical trial results for Olvi-Vec and the progress of V2ACT Immunotherapy and V-VET1. Key metrics to watch include clinical trial endpoints, regulatory milestones, and potential market size for their target indications. The inherent risks associated with drug development should also be considered when evaluating GNLX stock. Analyst ratings and price targets may vary depending on their assessment of these factors.
What are the main risks for GNLX?
The primary risks for Genelux Corporation are inherent to the biotechnology industry and include clinical trial failures, regulatory hurdles, and the need for substantial capital to fund ongoing research and development. Specifically, the success of Olvi-Vec is critical to the company's near-term prospects, and any setbacks in its clinical development could significantly impact the company's valuation. Competition from other companies developing cancer therapies also poses a risk. Additionally, Genelux faces the risk of patent expirations and the potential for biosimilar competition in the future.
How does Genelux Corporation manage patent expiration risks?
As a biotechnology company, Genelux Corporation faces the inherent challenge of managing patent expiration risks. The company actively seeks to extend the exclusivity of its key products, such as Olvi-Vec, through various strategies, including filing new patent applications for novel formulations, methods of use, and manufacturing processes. Additionally, Genelux may pursue regulatory exclusivity periods, such as orphan drug designation, to further protect its products from competition. Proactive lifecycle management is crucial for sustaining long-term revenue streams and mitigating the impact of patent cliffs.
What is Genelux Corporation's drug pipeline status?
Genelux Corporation's drug pipeline is centered around its oncolytic viral immunotherapy platform. The lead product candidate, Olvi-Vec, is currently in clinical development for ovarian cancer and non-small-cell lung cancer. V2ACT Immunotherapy is being developed for pancreatic cancer, and V-VET1 is being explored for hematologic and solid cancers. The company's pipeline represents a diversified approach to targeting various cancer types with its proprietary technology. Upcoming catalysts include clinical trial readouts, regulatory submissions, and potential partnerships.
What are the key factors to evaluate for GNLX?
Genelux Corporation (GNLX) holds an AI score of 15/100 (low). Not financial advice.
How frequently does GNLX data refresh on this page?
GNLX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GNLX's recent stock price performance?
Genelux Corporation (GNLX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary oncolytic virus technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- Clinical trial outcomes are inherently uncertain.